Testing a New Lymphoma Treatment Against a Standard One

Plain-English translation of NCT06337318 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a newer medication called works better than , a standard treatment for early-stage follicular lymphoma. Both are immunotherapy drugs that help your body's immune system fight the cancer. The trial will follow about 600 participants to see which treatment helps people live longer without their disease getting worse.

has been used for many years, but doctors want to know if newer treatments like can provide better results or fewer side effects for people with early-stage disease.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with follicular lymphoma (a type of blood cancer) and have not had any prior chemotherapy or immunotherapy
your lymphoma is considered 'low tumor burden,' meaning the tumors are relatively small and limited in number
you are experiencing distress from your disease or prefer active treatment rather than waiting to see if the disease progresses
you have had staging imaging (CT scans or PET scans) within the past 49 days
you are 18 years of age or older and in overall good health

You likely don't qualify if…

you have received prior systemic chemotherapy or immunotherapy for follicular lymphoma
your lymphoma has aggressive or unusual features (such as large cell or blastoid features)
you have B symptoms such as unexplained fevers, drenching sweats, or significant unintentional weight loss
you have very large tumors (greater than 7 cm) or more than 3 significantly enlarged tumor sites

What participation looks like

You will be randomly assigned to receive one of two treatments. If assigned to , you will receive injections or IV infusions roughly every 8 weeks for up to 5 cycles. If assigned to , you will receive injections every 3 weeks for up to 8 cycles. Either way, you will have regular CT or PET scans and blood tests to monitor how well the treatment is working. The study will continue to follow you after treatment ends to track your long-term health.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Testing a New Lymphoma Treatment Against a Standard One

What is this trial?

Do you qualify?

What participation looks like

Trial locations